BRCA Mutation clinical trials at UCSF
1 research study open to eligible people
A BRCA mutation is a change in genes that can increase the risk of cancer. UCSF is recruiting for a trial testing Olaparib and ASTX727 in people with BRCA1/2 mutations. This study looks at how these drugs work together to treat certain tumors.
Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
open to eligible people ages 18 years and up
This is a single center, phase I/Ib clinical trial evaluating the combination of the poly adenosine diphosphate-ribose polymerase (PARP) inhibitor olaparib with the DNA methyltransferase (DNMT) inhibitor ASTX727, which is an oral formulation of decitabine with cedazuridine (a cytidine deaminase inhibitor that allows for oral administration). The study population consists of adults with advanced/metastatic solid tumor malignancies with germline or somatic mutations in the HRR pathway (i.e., BReast CAncer gene 1 (BRCA1), BReast CAncer gene 2(BRCA2), Partner And Localizer of BRCA2 (PALB2), ATM, and/or Checkpoint kinase 2 (CHEK2) mutations).
San Francisco, California
Our lead scientists for BRCA Mutation research studies include Pamela Munster, MD.
Last updated: